Barry Chester

Barry Chester is a seasoned leader in oncology marketing with extensive experience at Pfizer since 2001. As the Global Commercial Lead for Supportive Care Oncology, Barry spearheaded the successful launch of the pegfilgrastim on-body injector, driving a supportive care portfolio that achieved 143% of the 2022 revenue budget, totaling $389 million. Previously, in the role of Portfolio Director, Barry launched Nyvepria and managed a portfolio that exceeded the 2020 budget by 123%, with net sales of $282 million. Barry's earlier positions included directing the launch of Pfizer’s first oncology biosimilars, leading to significant revenue achievements, and managing marketing strategies for hemophilia products that collectively generated over $400 million in annual sales. Barry holds an MBA from Babson F.W. Olin Graduate School of Business and has a background in Japanese language studies from Nanzan University, along with a bachelor's degree from St. Lawrence University.